CARMEN AURORA
RODRÍGUEZ CUETO
Profesora ayudante doctora
Publicaciones (22) Publicaciones de CARMEN AURORA RODRÍGUEZ CUETO
2024
-
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
Biomedicine and Pharmacotherapy, Vol. 174
2023
-
Endocannabinoid-Binding Receptors as Drug Targets
Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94
-
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
2021
-
Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 22
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Brain Pathology, Vol. 31, Núm. 6
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis
British Journal of Pharmacology
-
Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387
2020
-
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
Scientific Reports, Vol. 10, Núm. 1
2019
-
Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: Potential role in pathogenesis and expected relevance as neuroprotective targets
Frontiers in Molecular Neuroscience, Vol. 12
-
Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600
2018
-
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Biochemical Pharmacology, Vol. 157, pp. 217-226
2017
-
Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3
PLoS ONE, Vol. 12, Núm. 4
-
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412
-
Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558
2016
-
Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3
Neuroscience, Vol. 339, pp. 191-209
-
Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders
Frontiers in Neuroscience, Vol. 10, Núm. SEP
2014
-
Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias
British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489